# Eribulin

Source: https://onco.cc/drugs/eribulin/  
OnCo record `eribulin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A sea-sponge-derived chemotherapy that extended survival in heavily pretreated breast cancer and in liposarcoma, where almost nothing else had.

## Summary

EMBRACE (Lancet 2011): OS 13.1 vs 10.6 months versus treatment of physician's choice in pretreated metastatic breast cancer. Liposarcoma approval 2016 (OS 15.6 vs 8.4 months versus dacarbazine in the liposarcoma subgroup). Neuropathy and neutropenia; the payload of the ADC MORAb-202 (farletuzumab ecteribulin).

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill
- Brand: Halaven
- Modality: Synthetic halichondrin B analogue (microtubule dynamics inhibitor)
- Mechanism: Binds the plus ends of microtubules, suppressing growth without affecting shortening; also reverses EMT and remodels tumour vasculature.
- Approvals: US 2010: Metastatic breast cancer after ≥2 regimens including an anthracycline and a taxane; US 2016: Unresectable or metastatic liposarcoma after anthracycline; EU 2011: Metastatic breast cancer; liposarcoma (2016)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Eribulin
- EMBRACE (Lancet 2011): https://doi.org/10.1016/S0140-6736(11)60070-6
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eribulin

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Liposarcoma](https://onco.cc/cancers/liposarcoma/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Retroperitoneal sarcoma](https://onco.cc/cancers/retroperitoneal-sarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Soft tissue sarcoma of the extremity (localised and advanced)](https://onco.cc/cancers/extremity-soft-tissue-sarcoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Uterine sarcoma](https://onco.cc/cancers/uterine-sarcoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- companies: [Eisai](https://onco.cc/companies/eisai/), [GI Innovation](https://onco.cc/companies/gi-innovation/)
- terms: [Payload (ADC)](https://onco.cc/terms/payload/)
- trials: [A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct07441512/), [A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)](https://onco.cc/trials/nct06343948/), [A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o](https://onco.cc/trials/nct06435429/), [A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer](https://onco.cc/trials/nct03424005/), [A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06957886/), [A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer](https://onco.cc/trials/nct05570253/), [A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct06279364/), [A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06202261/), [A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu](https://onco.cc/trials/nct05824975/), [ASCENT](https://onco.cc/trials/ascent/), [Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)](https://onco.cc/trials/nct04639986/), [ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer](https://onco.cc/trials/nct07007559/), [Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)](https://onco.cc/trials/nct07255612/), [DESTINY-Breast04](https://onco.cc/trials/destiny-breast04/), [EMBRACA](https://onco.cc/trials/embraca/), [Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.](https://onco.cc/trials/nct05760378/), [JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC](https://onco.cc/trials/nct06731153/), [KEYNOTE-119](https://onco.cc/trials/keynote-119/), [LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer](https://onco.cc/trials/nct06387628/), [OlympiAD](https://onco.cc/trials/olympiad/), [Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer](https://onco.cc/trials/nct06889688/), [ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer](https://onco.cc/trials/nct07173751/), [Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy](https://onco.cc/trials/nct06449222/), [Scalp Cooling in MBC](https://onco.cc/trials/nct04986579/), [SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial](https://onco.cc/trials/nct05814354/), [Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct06202313/), [Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer](https://onco.cc/trials/nct06942234/), [Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer](https://onco.cc/trials/nct06081959/), [SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct03262935/), [Tucatinib+Trastuzumab+Eribulin in HER2+ MBC](https://onco.cc/trials/nct05458674/)
- key papers: [Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study](https://onco.cc/key-papers/paper-cortes-lancet/), [Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma](https://onco.cc/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/)
- targets: [Tubulin (microtubules)](https://onco.cc/targets/tubulin/)
- pathways: [Mitosis & the spindle assembly checkpoint](https://onco.cc/pathways/mitotic-spindle-checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/eribulin.json